Therapeutic Antibodies Against Cancer

被引：61

作者：

Adler, Mark J. ^{[1
,2
]}

Dimitrov, Dimiter S. ^{[3
]}

机构：

[1] Univ Calif Hlth Syst, Dept Med, UC San Diego Canc Ctr, Encinitas, CA 92024 USA

[2] San Diego Canc Res Inst, Encinitas, CA 92024 USA

[3] NIH, Frederick Natl Labs Canc Res, Frederick, MD 21702 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2012年 / 26卷 / 03期

关键词：

Therapeutics; Antibodies; Cancer; Immunogenicity; Safety; Efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; PHASE-III TRIAL; GROWTH-FACTOR RECEPTOR; METASTATIC COLORECTAL-CANCER; CETUXIMAB PLUS IRINOTECAN; PROGRESSION-FREE SURVIVAL; HUMAN MONOCLONAL-ANTIBODIES; BRENTUXIMAB VEDOTIN SGN-35; SQUAMOUS-CELL CARCINOMA; IN-SITU HYBRIDIZATION;

D O I：

10.1016/j.hoc.2012.02.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Antibody-based therapeutics against cancer are highly successful and currently enjoy unprecedented recognition of their potential; 13 monoclonal antibodies (mAbs) have been approved for clinical use in the European Union and in the United States. Bevacizumab, rituximab, and trastuzumab had sales in 2010 of more than $5 billion each. Hundreds of mAbs, including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small-molecule drugs, and mAbs with optimized pharmacokinetics, are in clinical trials. However, deeper understanding of mechanisms is needed to overcome major problems including resistance to therapy, access to targets, complexity of biological systems, and individual variations.

引用

页码：447 / +

页数：36

共 234 条

[1] PML problems loom for Rituxan [J].

Acton, Malorye Allison .

NATURE BIOTECHNOLOGY, 2010, 28 (02) :105-106

[2] Monoclonal antibody therapy of cancer [J].

Adams, GP ;

Weiner, LM .

NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157

[3] Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases [J].

Aikawa, Nadia Emi ;

de Carvalho, Jozelio Freire ;

Almeida Silva, Clovis Artur ;

Bonfa, Eloisa .

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2010, 38 (2-3) :82-89

[4] The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape [J].

Aldinucci, Donatella ;

Gloghini, Annunziata ;

Pinto, Antonio ;

De Filippi, Rosaria ;

Carbone, Antonino .

JOURNAL OF PATHOLOGY, 2010, 221 (03) :248-263

[5] Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Colangelo, Linda H. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

Goldberg, Richard M. ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Lopa, Samia ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16

[6] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].

Allegra, Carmen J. ;

Jessup, J. Milburn ;

Somerfield, Mark R. ;

Hamilton, Stanley R. ;

Hammond, Elizabeth H. ;

Hayes, Daniel F. ;

McAllister, Pamela K. ;

Morton, Roscoe F. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096

[7] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[8] Directing cancer cells to self-destruct with pro-apoptotic receptor agonists [J].

Ashkenazi, Avi .

NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (12) :1001-1012

[9] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[10] Management of bevacizumab-associated bowel perforation: a case series and review of the literature [J].

Badgwell, B. D. ;

Camp, E. R. ;

Feig, B. ;

Wolff, R. A. ;

Eng, C. ;

Ellis, L. M. ;

Cormier, J. N. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :577-582

← 1 2 3 4 5 6 7 8 9 10 →